VC-backed Genocea Biosciences prices IPO – Fortune

According to Fortune, Genocea Biosciences has priced its IPO of 5.5 million shares at between $12 and $14 a share. The stock will trade on the NASDAQ under the ticker symbol “GNCA.” Citigroup and Cowen & Co. are the lead underwriters. Based in Cambridge, Mass., Genocea Biosciences is a developer of T-cell vaccines.¬†Genocea’s backers include Polaris Venture Partners, Lux Ventures, Skyline Ventures, Auriga Ventures, The Bill & Melinda Gates Foundation and Morningside Ventures.